93 related articles for article (PubMed ID: 28579351)
1. Preclinical abuse liability assessment of ABT-126, an agonist at the α7 nicotinic acetylcholine receptor (nAChR).
Hudzik TJ; Basso AM; Lynch JJ; Bracken WM; Mohler EG; Kohlhaas KL; Xu H; Haig G; Gault L
Pharmacol Biochem Behav; 2017 Jul; 158():22-31. PubMed ID: 28579351
[TBL] [Abstract][Full Text] [Related]
2. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions.
Bordia T; McGregor M; Papke RL; Decker MW; McIntosh JM; Quik M
Exp Neurol; 2015 Jan; 263():277-84. PubMed ID: 25261754
[TBL] [Abstract][Full Text] [Related]
3. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
Bitner RS; Bunnelle WH; Decker MW; Drescher KU; Kohlhaas KL; Markosyan S; Marsh KC; Nikkel AL; Browman K; Radek R; Anderson DJ; Buccafusco J; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):875-86. PubMed ID: 20504913
[TBL] [Abstract][Full Text] [Related]
4. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
Boess FG; De Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Riedl B; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; Koenig G
J Pharmacol Exp Ther; 2007 May; 321(2):716-25. PubMed ID: 17308038
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
Malysz J; Anderson DJ; Grønlien JH; Ji J; Bunnelle WH; Håkerud M; Thorin-Hagene K; Ween H; Helfrich R; Hu M; Gubbins E; Gopalakrishnan S; Puttfarcken PS; Briggs CA; Li J; Meyer MD; Dyhring T; Ahring PK; Nielsen EØ; Peters D; Timmermann DB; Gopalakrishnan M
J Pharmacol Exp Ther; 2010 Sep; 334(3):863-74. PubMed ID: 20504915
[TBL] [Abstract][Full Text] [Related]
6. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
Radek RJ; Robb HM; Stevens KE; Gopalakrishnan M; Bitner RS
J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
[TBL] [Abstract][Full Text] [Related]
7. Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats.
Lee AM; Arreola AC; Kimmey BA; Schmidt HD
Behav Brain Res; 2014 Nov; 274():168-75. PubMed ID: 25128791
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist.
Boess FG; de Vry J; Erb C; Flessner T; Hendrix M; Luithle J; Methfessel C; Schnizler K; van der Staay FJ; van Kampen M; Wiese WB; König G
Psychopharmacology (Berl); 2013 May; 227(1):1-17. PubMed ID: 23241647
[TBL] [Abstract][Full Text] [Related]
9. The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys.
Zhang D; McGregor M; Decker MW; Quik M
J Pharmacol Exp Ther; 2014 Oct; 351(1):25-32. PubMed ID: 25034405
[TBL] [Abstract][Full Text] [Related]
10. Selective activation of α7 nicotinic acetylcholine receptors augments hippocampal oscillations.
Stoiljkovic M; Kelley C; Nagy D; Leventhal L; Hajós M
Neuropharmacology; 2016 Nov; 110(Pt A):102-108. PubMed ID: 27422408
[TBL] [Abstract][Full Text] [Related]
11. Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors.
Yohn NL; Turner JR; Blendy JA
J Pharmacol Exp Ther; 2014 May; 349(2):348-54. PubMed ID: 24627467
[TBL] [Abstract][Full Text] [Related]
12. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain.
Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A
Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933
[TBL] [Abstract][Full Text] [Related]
13. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
Hashimoto K
Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
[TBL] [Abstract][Full Text] [Related]
14. Nicotine increases eclampsia-like seizure threshold and attenuates microglial activity in rat hippocampus through the α7 nicotinic acetylcholine receptor.
Li X; Han X; Bao J; Liu Y; Ye A; Thakur M; Liu H
Brain Res; 2016 Jul; 1642():487-496. PubMed ID: 27106269
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of the α7-Nicotinic Acetylcholine Receptor Agonist ABT-126 in the Treatment of Cognitive Impairment Associated With Schizophrenia: Results From a Phase 2b Randomized Controlled Study in Smokers.
Haig GM; Wang D; Zhao J; Othman AA; Bain EE
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 28922590
[TBL] [Abstract][Full Text] [Related]
16. SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation.
Cohen C; Bergis OE; Galli F; Lochead AW; Jegham S; Biton B; Leonardon J; Avenet P; Sgard F; Besnard F; Graham D; Coste A; Oblin A; Curet O; Voltz C; Gardes A; Caille D; Perrault G; George P; Soubrie P; Scatton B
J Pharmacol Exp Ther; 2003 Jul; 306(1):407-20. PubMed ID: 12682217
[TBL] [Abstract][Full Text] [Related]
17. Ligands selective for alpha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat.
Smith JW; Mogg A; Tafi E; Peacey E; Pullar IA; Szekeres P; Tricklebank M
Psychopharmacology (Berl); 2007 Feb; 190(2):157-70. PubMed ID: 17115136
[TBL] [Abstract][Full Text] [Related]
18. Prefrontal beta2 subunit-containing and alpha7 nicotinic acetylcholine receptors differentially control glutamatergic and cholinergic signaling.
Parikh V; Ji J; Decker MW; Sarter M
J Neurosci; 2010 Mar; 30(9):3518-30. PubMed ID: 20203212
[TBL] [Abstract][Full Text] [Related]
19. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats.
Paterson NE; Min W; Hackett A; Lowe D; Hanania T; Caldarone B; Ghavami A
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1455-64. PubMed ID: 20708056
[TBL] [Abstract][Full Text] [Related]
20. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
Prickaerts J; van Goethem NP; Chesworth R; Shapiro G; Boess FG; Methfessel C; Reneerkens OA; Flood DG; Hilt D; Gawryl M; Bertrand S; Bertrand D; König G
Neuropharmacology; 2012 Feb; 62(2):1099-110. PubMed ID: 22085888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
